Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kaken to Increase Its No. of MRs to 800
November 22, 2010
- Yakult Honsha: Elplat Drives Pharma Business
November 22, 2010
- Eribulin Approved by FDA: Eisai
November 22, 2010
- Combined Sales of 23 Listed JPMA Member Companies Up 1.4%
November 22, 2010
- Sato to Launch Switch OTC Steroidal Agent
November 22, 2010
- GRU Criticizes Korosho for Not Discussing Range of OTC-like Drugs to Be Excluded from Insurance Coverage
November 22, 2010
- Kyorin: Sales Up 2.2% Driven by Kipres
November 22, 2010
- Price Settlement Rate 49.8% as of Sept. 30: CEO Kumakura of MEDIPAL
November 22, 2010
- Need for Economic Assessment of Drugs Pointed Out at Chuikyo
November 22, 2010
- Nippon Shinyaku: Cialis Drives Sales
November 22, 2010
- Alfresa: Operating Profits More than Double
November 22, 2010
- Afinitor Approved for Brain Tumors: Novartis
November 22, 2010
- Zeria: Asacol Drives Sales, Profits
November 22, 2010
- Suzuken: Operating Loss Reported for the First Time
November 22, 2010
- Enroll Japanese Patients in Early-Stage Global Studies
November 22, 2010
- Fuso: Generics Make Up for Decreases in Sales
November 22, 2010
- Toho: Sales Up 9.1% Boosted by Addition of SAYWELL
November 22, 2010
- EFPIA Survey Shows “Over-Quality” of Clinical Trials in Japan
November 22, 2010
- Torii: New Products Drive Sales
November 22, 2010
- VITAL KSK: Sales Remain Virtually Flat
November 22, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…